Given the established role of NAC in the preoperative management of locally advanced breast cancer and selected triple-negative or HER2-positive subtypes (24, 25), a comprehensive understanding of its associated risks is clinically imperative. This evidence concerns the gene ERBB2 and breast carcinoma.